TITANIUM PROFESSIONALS

A group of scientists led by Joseph Brown, assistant professor at the Leslie Dan Faculty of Pharmacy, has received $2.3 million USD in funding to develop a database and AI training model to identify peptides with therapeutic potential. The project is funded through the Google.org Impact Challenge: AI for Science initiative.

The newly funded initiative, OpenPep, will lead to an open access database that will allow researchers to use artificial intelligence (AI) to predict which peptides will bind to target proteins.

The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines. The guidance ends longstanding uncertainty by providing recommendations about when app content is subject to FDA submission requirements, when an app should be mentioned on a drug’s official label, and what companies should submit to the agency.

A team of scientists in Norway has found evidence for a new, previously unknown mechanism for the development of cancer in children: they seem to produce an unusual amount of aberrant antibodies against the building blocks that make up the DNA repair machinery, a diverse set of hundreds of proteins which identify and correct damage or errors in the genome. This important discovery could open the door to the early screening of small children, in the hope of ultimately preventing them from developing such pediatric cancers years in their teenage years.

Aggressive tumors often contain large amounts of exchromosomal DNA. Removing this DNA from the nuclei of cancer cells could improve patient outcomes, an international team led by Anton Henssen of the Experimental and Clinical Research Center reports in Nature Genetics.

Cells from rapidly growing, highly metastatic tumors often contain numerous rings of extrachromosomal DNA (ecDNA).

Abbott, the global healthcare leader, launched “Mind Your Behind,” a new Cologuard Plus® awareness campaign featuring baseball legend and three-time MVP Albert “The Machine” Pujols and catcher for the Seattle Mariners Cal “The Big Dumper” Raleigh to encourage adults to prioritize colorectal cancer screening.

Almost one billion people are projected to be living with osteoarthritis by 2050, up from about 600 million in 2023, and there remains no cure and no drug that can stop or slow the disease, according to a new roadmap published in The Lancet.

A Curtin University-led group of international researchers is calling for stronger health policy action to arrest the growing global disability burden.

Doctors’ prescribing habits are heavily influenced by payments, gifts, and free meals from pharmaceutical companies, leading to more expensive, less appropriate and more drugs being prescribed, a new Cochrane review finds. This can seriously harm both individual patients and health systems.

Pharmaceutical companies use a variety of strategies to market and promote their drugs.

A scientist at Weill Cornell Medicine is working with colleagues at the University of Massachusetts Amherst on new, complementary research efforts engineering therapeutic Salmonella to target critical gaps in treatment for drug-resistant triple-negative breast cancers. The team has received a five-year, $13.1 million grant, the first of its kind for bacteria cancer therapies awarded by the U.S. National Institutes of Health,

Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, including Alzheimer’s disease, in which twisted clumps of a protein called tau accumulate in the brain. Cells near those clumps begin to die after tau accumulates, but growing evidence suggests that much of the damage doesn’t come from the protein directly.

Adults with hard-to-treat epilepsy who used cannabis most days had more than twice as many convulsive seizures per year and more rapidly became resistant to antiseizure medications compared with nonusers, according to new research from Washington University School of Medicine in St. Louis. The study appears in the journal Epilepsia.

RNA vaccines and other nucleic acid therapeutics are typically packaged within fatty molecules known as lipid nanoparticles (LNPs). MIT researchers have now come up with a way to produce these particles much more quickly, and with more precise control over their size and shape.

Minutes count when a patient with a stroke arrives at the hospital emergency room. Doctors stand ready to treat, but whether the blood clot can be removed medically depends on what medication the patient is already taking. Even if a blood sample is rushed through the laboratory, results can take up to an hour to arrive.

Streptococcus pneumoniae is a bacterial pathogen that causes life-threatening infections, including pneumonia and meningitis. These infections are commonly treated with antibiotics, but antibiotics are becoming less effective against S. pneumoniae over time due to changes in the pathogen that cause drug resistance. This phenomenon, called antimicrobial resistance, is resulting in significant healthcare costs and deaths around the world.

The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects,

New US Medicare pricing policies could reshape global pharmaceutical markets, potentially driving up prices and delaying medicine launches worldwide, study suggests. A new modelling study published in The Lancet suggests that US Medicare's new 'Most-Favoured-Nation' pricing policy [1], which ties what Medicare pays for medicines to prices charged in other high-income countries,

Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer.

Investigators at Cedars-Sinai Health Sciences University used an experimental drug to reverse the effects of systemic sclerosis, a serious autoimmune disease. The study, conducted in a laboratory, was published in JCI Insight.

Systemic sclerosis, also called scleroderma, is a chronic, life-threatening condition that scars the skin, lungs, heart and other organs.

We are proud Europeans. We serve as Chairs of companies born from European science, rooted in laboratories across Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, the UK, and beyond. Our duty is to safeguard our companies’ future so that we can continue to discover and develop life-changing medicines for patients.

The pharmaceutical sector is one of our continent's great post-war achievements. Built on investment in science, world-class universities, and the determination to discover medicines that change lives.

Pushing the accelerator and the brake at the same time is rarely a good idea. But researchers at the University of Gothenburg are using this approach to treat leukemia. A new drug forces cancer cells to keep working hard even though they have run out of energy. The first study in mice shows very promising results.

A team led by Leif Eriksson at the University of Gothenburg and Boaz Tirosh at Case Western Reserve University in Cleveland has developed a new treatment for acute myeloid leukemia (AML).